FlowCardia, Inc. Announces Availability of the Peripheral CROSSER(TM) Catheter Portfolio in Europe - a New, Endovascular Option to Amputation and Bypass Surgery
Share:
SUNNYVALE, Calif., Jan. 25 -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, announced availability of the CROSSER(TM) 14P, CROSSER(TM) 14S and CROSSER(TM) 18 CTO Recanalization Catheters in the European Union. The Peripheral CROSSER Catheters are designed to facilitate the placement of guidewires beyond vessel narrowing and CTOs in leg arteries.
The three peripheral CROSSER Catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to safely and quickly cross CTOs to help restore blood flow to the lower legs. The CROSSER Catheters are delivered using standard guidewires to the site of the occlusion in the legs. The CROSSER Catheters then utilize high-frequency vibration to facilitate guidewire crossing of the occlusion allowing for subsequent plaque debulking (removal), balloon angioplasty or stent placement. For many patients, this cath-lab based, minimally invasive approach to CTO recanalization can eliminate the need for potentially traumatic bypass graft surgery or leg amputation.
The CROSSER 14P, 14S and 18 Catheter European introduction follows the completion of over 380 coronary and peripheral CROSSER Catheter CTO cases throughout the US and Europe.
"The entire FlowCardia coronary and peripheral CROSSER Catheter portfolio is now available for European Union distribution," said Wick Goodspeed, President and CEO of FlowCardia. "We are very eager to offer the European interventionalists a significantly less invasive therapeutic option for their coronary and peripheral chronic total occlusion patients."
FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture safe and effective, endovascular CTO recanalization systems. Additional information is available on the Company's new Web Site at http://www.flowcardia.com/.
CONTACT:
Mark Page
Director, Marketing
FlowCardia, Inc.
408-617-0352 ext. 301
Source: FlowCardia, Inc.
Web site: http://www.flowcardia.com/
